It’s called Muvalaplin and it’s the first oral drug that can reduce levels of Lp(a), a form of cholesterol that increases the risk of heart attack and stroke, by interrupting its ability to form in the body.
From a new drug comes an innovative treatment for lipoprotein (a)shape of cholesterol largely genetic which increases the risk of stroke from stroke. To announce it is the professor Stephen Nichollsauthor of the related study and director of the Victorian Heart Institute of the Monash University in Melbourne (Australia).
The study demonstrated the success of Muvalaplin, the first oral drug ever developed to target Lp(a), effectively reducing its levels by up to 65% and disrupting its ability to form in the body. The findings were presented at the Congress of the European Society of Cardiology in Amsterdam and published in Jama.
Advertisements
Lp(a) is similar to LDL cholesterol, also known as ‘bad cholesterol’, but it is ‘stickier’, increasing the risk of blockages and blood clots in the arteries. Common LDL-lowering drugs, such as statins, do not have the same Lp(a)-lowering effect. Being largely genetic, Lp(a) is also difficult to control through diet, exercise and other lifestyle changes.
“This drug is a game changer in more ways than one,” says Professor Nicholls. Not only do we have an option to lower an elusive form of cholesterol, but we’re also able to deliver it with an oral tablet. This means it will be more accessible for patients.”
Full text of the article on Jama
Nurse Times editorial team
Follow our Telegram group “Competitions and announcements for nurses and obs”
2023-08-29 17:00:00
#Cholesterol #developed #drug #affects #lipoprotein
:format(url)/cloudfront-us-east-1.images.arcpublishing.com/lescoopsdelinformation/S4BS3KCL5RHV5GEFIRESIUYEVY.jpg?resize=150%2C150&ssl=1)